Novo Nordisk Announces Insider Share Transactions

The latest announcement is out from Novo Nordisk ( (NVO) ).

On November 17, 2025, Novo Nordisk announced transactions involving its shares by board members, executives, and associated persons, in compliance with market abuse regulations. Stephan Engels, a board member, purchased 6,450 shares at a price of DKK 312.50 per share, totaling DKK 2,015,625. This transaction, conducted on Nasdaq Copenhagen, highlights the ongoing engagement of company insiders with Novo Nordisk’s stock, potentially signaling confidence in the company’s future performance.

The most recent analyst rating on (NVO) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.

Novo Nordisk’s strong financial performance and reasonable valuation are key strengths, supporting a solid overall score. However, bearish technical indicators and challenges highlighted in the earnings call, such as market share loss and restructuring, weigh on the score. The company’s strategic focus on long-term growth and attractive dividend yield provide additional support.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly through its heritage in diabetes treatment. It employs about 78,400 people across 80 countries and markets its products in approximately 170 countries. Novo Nordisk’s shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.

Average Trading Volume: 15,485,517

Technical Sentiment Signal: Sell

Current Market Cap: $214.5B

Learn more about NVO stock on TipRanks’ Stock Analysis page.